Warner Financial Inc. Has $1.57 Million Stake in Pfizer Inc. (NYSE:PFE)

Posted by Defense World Staff on Jul 9th, 2023

Warner Financial Inc. lifted its position in Pfizer Inc. (NYSE:PFE – Free Report) by 35.1% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 38,358 shares of the biopharmaceutical company’s stock after buying an additional 9,969 shares during the quarter. Pfizer comprises 1.1% of Warner Financial Inc.’s investment portfolio, making the stock its 23rd largest holding. Warner Financial Inc.’s holdings in Pfizer were worth $1,565,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in PFE. Lam Group Inc. bought a new stake in Pfizer during the fourth quarter worth approximately $25,000. Worth Asset Management LLC bought a new stake in Pfizer during the first quarter worth approximately $29,000. My Personal CFO LLC bought a new stake in Pfizer during the fourth quarter worth approximately $32,000. Mendota Financial Group LLC bought a new stake in Pfizer during the fourth quarter worth approximately $33,000. Finally, Freedom Wealth Alliance LLC bought a new stake in Pfizer during the fourth quarter worth approximately $35,000. Institutional investors own 67.80% of the company’s stock.

Insiders Place Their Bets

In related news, Director Scott Gottlieb acquired 1,000 shares of the company’s stock in a transaction on Monday, May 8th. The stock was purchased at an average cost of $38.58 per share, for a total transaction of $38,580.00. Following the completion of the purchase, the director now directly owns 6,000 shares of the company’s stock, valued at approximately $231,480. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.05% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on PFE shares. StockNews.com cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, June 30th. Wells Fargo & Company decreased their target price on Pfizer from $50.00 to $44.00 and set an “equal weight” rating for the company in a research report on Friday, March 17th. Credit Suisse Group cut Pfizer from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $47.00 to $40.00 in a research report on Thursday, June 29th. Barclays reduced their price objective on Pfizer from $43.00 to $40.00 in a research report on Wednesday, May 3rd. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Pfizer in a research report on Wednesday, May 17th. Eleven research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $46.67.

Pfizer Stock Performance

Shares of NYSE PFE opened at $35.53 on Friday. The business has a fifty day simple moving average of $38.03 and a 200 day simple moving average of $41.57. The company has a current ratio of 1.37, a quick ratio of 1.11 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $200.58 billion, a price-to-earnings ratio of 6.99, a PEG ratio of 1.18 and a beta of 0.61. Pfizer Inc. has a one year low of $35.35 and a one year high of $54.93.

Pfizer (NYSE:PFE – Free Report) last issued its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $1.23 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.23. Pfizer had a return on equity of 37.53% and a net margin of 31.25%. The business had revenue of $18.28 billion during the quarter, compared to analyst estimates of $16.49 billion. During the same period in the prior year, the company posted $1.62 earnings per share. Pfizer’s revenue was down 28.8% on a year-over-year basis. Sell-side analysts expect that Pfizer Inc. will post 3.35 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 5th. Shareholders of record on Friday, July 28th will be paid a dividend of $0.41 per share. The ex-dividend date is Thursday, July 27th. This represents a $1.64 annualized dividend and a yield of 4.62%. Pfizer’s dividend payout ratio is currently 32.28%.

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.